Xaira Therapeutics

Xaira's X-Cell model card reports evaluation on held-out iPSC perturbations, with Pearson delta five times the next-best method, and zero-shot generalization to melanocyte progenitors and primary human CD4+ T cells. It identifies training on 25.6 million perturbed single cells across seven CRISPRi screens. These author-reported research evaluations are distinct from generic dataset/model release; no patient efficacy or therapeutic approval is established, and weights/code are listed as forthcoming.

Xaira has advanced platform and preclinical programs and released major biological datasets and virtual-cell models, but broad clinical or commercial therapeutic impact remains early.

Xaira has advanced platform and preclinical programs and released major biological datasets and virtual-cell models, but broad clinical or commercial therapeutic impact remains early.

Xaira’s X-Suite combines X-Cell causal single-cell models, X-Design generative therapeutic design, X-Patient patient-response modeling, X-Scientist multi-agent drug discovery and X-Automate physical-AI wet-lab automation in a closed-loop AI-powered therapeutics engine.

Xaira launched X-Cell, a diffusion-language virtual-cell model trained on the largest-ever genome-wide perturbation dataset, alongside causal biological modeling and AI-driven drug discovery.

Xaira launched X-Cell, a diffusion-language virtual-cell model trained on the largest-ever genome-wide perturbation dataset, alongside causal biological modeling and AI-driven drug discovery.

Xaira was launched with more than $1B in committed capital and has assembled integrated AI and drug-development leadership spanning computational biology, therapeutic design, translational science, clinical development and automated experimentation.

Xaira launched with nearly $1B in financing and has assembled senior scientific, translational, drug-development and AI leadership to build an integrated AI-native therapeutics company.

Xaira launched with nearly $1B in financing and has assembled senior scientific, translational, drug-development and AI leadership to build an integrated AI-native therapeutics company.

Xaira describes X-Scientist as a multi-agent system coordinating X-Cell, X-Design and X-Patient, alongside X-Automate robotics that execute wet-lab workflows and generate experimental trajectories for learning. These specific orchestration and experimental-automation workflows support an inference of portable agent and data-system skills beyond the existing general biological-modeling evidence.

Foundation-model, causal biology and computational drug-discovery skills transfer strongly across TechBio and life-sciences AI, but biology and therapeutics specialization constrain universal portability.

Foundation-model, causal biology and computational drug-discovery skills transfer strongly across TechBio and life-sciences AI, but biology and therapeutics specialization constrain universal portability.